Annals of Oncology路 @Annals_Oncology 路 X路路 1 day agoScore70
Body
馃摙 #ESMO26 concomitant paper: OS from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs pbo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy.
馃敆https://tinyurl.com/mt82dufd
@KalinskyKevin @BianchiniGP
197 views 路 2 likes 路 3 reposts 路 0 replies
Conference abstracts
1ROmatched by Rapid oral 1: Breast cancer, advanced stage
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgSource: Annals of Oncology 路 x.com